Alstrom syndrome is a rare autosomal recessive multisystem ciliopathy caused by biallelic ALMS1 loss-of-function variants. The disease combines early retinal degeneration and progressive sensorineural hearing loss with childhood obesity, insulin resistance, type II diabetes mellitus, cardiomyopathy, and progressive kidney and liver involvement. The central mechanistic theme is ALMS1 dysfunction at centrosomes and ciliary basal bodies, with downstream defects in adipose tissue biology, sensory-cell maintenance, and fibrotic remodeling.
Ask a research question about Alstrom Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Alstrom Syndrome
creation_date: '2026-04-12T20:00:00Z'
updated_date: '2026-04-22T20:13:21Z'
description: >-
Alstrom syndrome is a rare autosomal recessive multisystem ciliopathy caused by
biallelic ALMS1 loss-of-function variants. The disease combines early retinal
degeneration and progressive sensorineural hearing loss with childhood obesity,
insulin resistance, type II diabetes mellitus, cardiomyopathy, and progressive
kidney and liver involvement. The central mechanistic theme is ALMS1
dysfunction at centrosomes and ciliary basal bodies, with downstream defects
in adipose tissue biology, sensory-cell maintenance, and fibrotic remodeling.
category: Genetic
parents:
- Syndromic Obesity
- Ciliopathy
disease_term:
preferred_term: Alstrom syndrome
description: Rare autosomal recessive ALMS1-related multisystem ciliopathy.
term:
id: MONDO:0008763
label: Alstrom syndrome
prevalence:
- population: Global
percentage: 1 in 1,000,000
evidence:
- reference: PMID:33566311
reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BACKGROUND: Alström syndrome (ALMS) is a monogenic ultra-rare disorder with a prevalence of one per million inhabitants caused by pathogenic variants of ALMS1 gene."
explanation: Review of ALMS clinical and molecular literature provides a conventional global prevalence estimate of about one per million.
inheritance:
- name: Autosomal recessive
inheritance_term:
preferred_term: Autosomal recessive inheritance
term:
id: HP:0000007
label: Autosomal recessive inheritance
expressivity: VARIABLE
description: >-
Alstrom syndrome is caused by biallelic germline ALMS1 variants and shows
marked age-dependent variability, including transient infantile
cardiomyopathy in some patients and later adult cardiomyopathy in others.
evidence:
- reference: PMID:11941369
reference_title: "Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Alström syndrome is a homogeneous autosomal recessive disorder that is characterized by childhood obesity associated with hyperinsulinemia, chronic hyperglycemia and neurosensory deficits."
explanation: Landmark discovery paper states the autosomal recessive inheritance pattern.
- reference: PMID:38806112
reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BACKGROUND: >40% of infants with Alström Syndrome (AS) present with a transient, severe cardiomyopathy in the first months of life, with apparent recovery in survivors. One in five individuals then develop a later-onset cardiomyopathy but wide clinical variability is observed, even within the same family."
explanation: Adult cardiovascular cohort demonstrates variable expressivity across the lifespan and even within families.
genetic:
- name: ALMS1
gene_term:
preferred_term: ALMS1
term:
id: hgnc:428
label: ALMS1
association: Causative
features: >-
Biallelic truncating variants predominate, with many pathogenic alleles
clustered in exons 8, 10, and 16. Large cohort studies continue to expand
the mutational spectrum and suggest genotype-phenotype enrichment of
infantile cardiomyopathy with exon 16 truncating variants.
inheritance:
- name: Autosomal recessive
evidence:
- reference: PMID:11941370
reference_title: "Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We have detected six different mutations (two nonsense and four frameshift mutations causing premature stop codons) in seven families, confirming that ALMS1 is the gene underlying Alström syndrome."
explanation: Original positional cloning study establishes ALMS1 as the causative gene and shows recurrent truncating alleles.
- reference: PMID:41466426
reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "A total of 132 distinct ALMS1 variants (254 alleles) were identified, including 64 novel variants. Truncating mutations predominated (nonsense: 46.9%, frameshift: 45.3%)."
explanation: Large contemporary cohort confirms that truncating ALMS1 variants predominate and substantially expands the pathogenic variant spectrum.
pathophysiology:
- name: ALMS1 Basal Body Dysfunction
conforms_to: "ciliopathy_dysfunction#Basal Body and Transition Zone Dysfunction"
description: >-
ALMS1 is a centrosome and ciliary basal body-associated protein. Loss of
ALMS1 function disrupts basal-body dependent cellular organization across
multiple tissues and acts as the upstream lesion for the sensory, renal,
metabolic, and fibrotic components of Alstrom syndrome.
gene:
preferred_term: ALMS1
modifier: DECREASED
term:
id: hgnc:428
label: ALMS1
cellular_components:
- preferred_term: centrosome
term:
id: GO:0005813
label: centrosome
- preferred_term: ciliary basal body
term:
id: GO:0036064
label: ciliary basal body
evidence:
- reference: PMID:15855349
reference_title: "Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We show that ALMS1 is widely expressed and localizes to centrosomes and to the base of cilia."
explanation: Cell localization experiments place ALMS1 at the centrosome and basal body, supporting a primary ciliary-basal body mechanism.
- reference: PMID:11941370
reference_title: "Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "We have detected six different mutations (two nonsense and four frameshift mutations causing premature stop codons) in seven families, confirming that ALMS1 is the gene underlying Alström syndrome."
explanation: Human genetic evidence links ALMS1 loss to disease and anchors basal body dysfunction as the upstream defect.
downstream:
- target: Relative Adipose Tissue Failure
description: ALMS1 loss compromises adipose tissue buffering capacity and promotes metabolically adverse obesity.
- target: Extracellular Matrix Dysregulation
description: Cilia-linked signaling defects alter matrix remodeling programs and favor multiorgan fibrotic disease.
- target: Kidney Ciliary Dysfunction
description: Renal tubular primary cilia lose normal maintenance and mechanosensory function.
- target: Photoreceptor Degeneration
description: Photoreceptor cells progressively fail when ALMS1-dependent ciliary trafficking is lost.
- target: Cochlear Outer Hair Cell Degeneration
description: Hair-cell basal body dysfunction perturbs inner-ear sensory-cell polarity and survival.
- name: Relative Adipose Tissue Failure
description: >-
Obesity in Alstrom syndrome is accompanied by inadequate adipose tissue
expansion and adipocyte dysfunction, producing a metabolically fragile state
in which insulin resistance develops early and progresses rapidly.
cell_types:
- preferred_term: adipocyte
term:
id: CL:0000136
label: adipocyte
evidence:
- reference: PMID:32994277
reference_title: "Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Hence, we show for the first time the relative AT failure in human obese cohorts to be a major determinant of accelerated IR without evidence of lipodystrophy."
explanation: Human metabolic phenotyping identifies relative adipose tissue failure as a proximal mechanism for insulin-resistant obesity in Alstrom syndrome.
downstream:
- target: Insulin resistance
description: Limited adipose buffering capacity accelerates systemic insulin resistance.
- target: Type II diabetes mellitus
description: Progressive insulin resistance drives diabetes as beta-cell compensation fails.
evidence:
- reference: PMID:33566311
reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In addition, infantile transient cardiomyopathy, early childhood obesity with hyperphagia, deafness, insulin resistance (IR), type 2 diabetes mellitus (T2DM), systemic fibrosis and progressive renal or liver dysfunction are common findings."
explanation: Clinical review supports type II diabetes mellitus as a common downstream metabolic manifestation of ALMS.
- target: Hypertriglyceridemia
description: Adipose tissue failure is accompanied by dyslipidemia with elevated triglycerides.
- name: Extracellular Matrix Dysregulation
description: >-
ALMS1 deficiency alters extracellular matrix regulatory programs, favoring
collagen remodeling and fibroproliferative disease in liver and heart.
cell_types:
- preferred_term: fibroblast
term:
id: CL:0000057
label: fibroblast
biological_processes:
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
- preferred_term: collagen fibril organization
term:
id: GO:0030199
label: collagen fibril organization
evidence:
- reference: PMID:38062477
reference_title: "Loss of the centrosomal protein ALMS1 alters lipid metabolism and the regulation of extracellular matrix-related processes."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "alterations associated with ALMS1 depletion clustered around the processes of extracellular matrix regulation and lipid metabolism in both the transcriptome and proteome."
explanation: ALMS1 knockout fibroblast profiling directly links ALMS1 deficiency to extracellular matrix dysregulation.
downstream:
- target: Hepatic steatosis
description: Matrix dysregulation accompanies common steatotic liver involvement in Alstrom syndrome.
evidence:
- reference: PMID:33924909
reference_title: "Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Patients with ALMS displayed enhanced steatosis, an early increased age-dependent LS that is associated with obesity and T2DM but also linked to genetic alterations, suggesting that ALMS1 could be involved in liver fibrogenesis."
explanation: Human liver elastography and ultrasound data support common steatotic and fibrogenic liver disease in ALMS.
- target: Cardiac Fibroelastotic Remodeling
description: Abnormal matrix remodeling contributes to infantile fibroelastosis and later adult cardiomyopathy.
- name: Kidney Ciliary Dysfunction
conforms_to: "ciliopathy_dysfunction#Renal Tubular Cystic and Fibrotic Disease"
description: >-
Renal disease in Alstrom syndrome reflects a primary nephron ciliopathy
rather than merely secondary metabolic injury, with progressive tubular
ciliary loss and impaired mechanosensory signaling.
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
locations:
- preferred_term: kidney
term:
id: UBERON:0002113
label: kidney
biological_processes:
- preferred_term: cilium organization
term:
id: GO:0044782
label: cilium organization
- preferred_term: cellular response to mechanical stimulus
modifier: DECREASED
term:
id: GO:0071260
label: cellular response to mechanical stimulus
evidence:
- reference: PMID:17206865
reference_title: "A role for Alström syndrome protein, alms1, in kidney ciliogenesis and cellular quiescence."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Here, we show that in vitro knockdown of Alms1 in mice causes stunted cilia on kidney epithelial cells and prevents these cells from increasing calcium influx in response to mechanical stimuli."
explanation: Mouse kidney epithelial experiments show direct impairment of renal cilia morphology and mechanosensory signaling.
- reference: PMID:30064963
reference_title: "Alström syndrome: Renal findings in correlation with obesity, insulin resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively evaluated at the NIH clinical center."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "After adjusting for age, there were no significant associations of kidney dysfunction with type 2 diabetes mellitus, dyslipidemia, hypertension, cardiomyopathy or portal hypertension suggesting that kidney disease in AS is a primary manifestation of the syndrome due to lack of ALMS1 protein."
explanation: Human cohort data argue that kidney disease is a primary manifestation of ALMS rather than a secondary metabolic complication.
downstream:
- target: Chronic kidney disease
description: Primary renal involvement progresses with age to chronic kidney disease.
- name: Photoreceptor Degeneration
conforms_to: "ciliopathy_dysfunction#Photoreceptor Connecting Cilium Degeneration"
description: >-
ALMS1 deficiency disrupts photoreceptor intracellular trafficking and drives
progressive cone and rod degeneration, producing the characteristic retinal
dystrophy of Alstrom syndrome.
cell_types:
- preferred_term: retinal cone cell
term:
id: CL:0000573
label: retinal cone cell
- preferred_term: retinal rod cell
term:
id: CL:0000604
label: retinal rod cell
locations:
- preferred_term: retina
term:
id: UBERON:0000966
label: retina
evidence:
- reference: PMID:16000322
reference_title: "Alms1-disrupted mice recapitulate human Alström syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "Diminished cone ERG b-wave response is observed early, followed by the degeneration of photoreceptor cells."
explanation: The Alms1 mouse model directly demonstrates progressive photoreceptor degeneration.
- reference: PMID:41466426
reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "BACKGROUND: Alström syndrome (ALMS) is a rare autosomal recessive multisystem disorder caused by biallelic pathogenic variants in the ALMS1 gene, characterized by progressive cone-rod dystrophy, early-onset obesity, cardiomyopathy, and multiorgan dysfunction."
explanation: Large human cohort framing confirms progressive cone-rod dystrophy as a core disease manifestation.
downstream:
- target: Cone/cone-rod dystrophy
description: Progressive cone and rod loss produces the hallmark retinal dystrophy.
- target: Visual impairment
description: Early photoreceptor loss causes severe lifelong visual disability.
- name: Cochlear Outer Hair Cell Degeneration
description: >-
ALMS1 localizes to cochlear hair-cell basal bodies; its loss perturbs planar
cell polarity and outer hair cell survival, producing progressive sensory
hearing loss.
cell_types:
- preferred_term: cochlear outer hair cell
term:
id: CL:0000601
label: cochlear outer hair cell
locations:
- preferred_term: cochlea
term:
id: UBERON:0001844
label: cochlea
evidence:
- reference: PMID:21071598
reference_title: "Alström Syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: "These results identify previously unrecognized cochlear histopathologies associated with this ciliopathy that (i) implicate ALMS1 in planar cell polarity signaling and (ii) suggest that the loss of outer hair cells causes the majority of the hearing loss in Alström Syndrome."
explanation: Mouse inner-ear studies support outer hair cell loss as the proximal lesion driving ALMS hearing loss.
- reference: PMID:28573831
reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Absent otoacoustic emissions, intact speech discrimination, and disproportionately normal auditory brainstem responses suggest an outer hair cell site of lesion."
explanation: Human audiologic phenotyping independently supports an outer hair cell lesion.
downstream:
- target: Sensorineural hearing impairment
description: Progressive predominantly sensory hearing loss reflects outer hair cell dysfunction and loss.
- name: Cardiac Fibroelastotic Remodeling
description: >-
Cardiac disease in Alstrom syndrome spans infantile fibroelastotic
cardiomyopathy and later adult myocardial remodeling, with both
cardiomyocyte and cardiac fibroblast abnormalities implicated.
cell_types:
- preferred_term: cardiac muscle cell
term:
id: CL:0000746
label: cardiac muscle cell
- preferred_term: fibroblast of cardiac tissue
term:
id: CL:0002548
label: fibroblast of cardiac tissue
locations:
- preferred_term: heart
term:
id: UBERON:0000948
label: heart
biological_processes:
- preferred_term: extracellular matrix organization
term:
id: GO:0030198
label: extracellular matrix organization
evidence:
- reference: PMID:34387706
reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
explanation: Pathology-confirmed case shows that infantile ALMS cardiomyopathy can present as primary endocardial fibroelastosis.
- reference: PMID:34387706
reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "ALMS1-depleted cardiomyocytes exhibited enhanced proliferation activity."
explanation: Functional studies in patient-derived systems implicate direct cardiomyocyte remodeling effects of ALMS1 deficiency.
- reference: PMID:38806112
reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cardiomyopathy is common in adults with AS, complicated in a significant proportion by atherosclerotic coronary artery disease and restrictive cardiomyopathy, confirmed on CMR and invasive testing."
explanation: Adult cohort data show persistent structural and functional cardiac remodeling beyond infantile disease.
downstream:
- target: Dilated cardiomyopathy
description: Infantile and adult myocardial remodeling commonly manifests as cardiomyopathy.
histopathology:
- name: Endocardial fibroelastosis
finding_term:
preferred_term: Cardiac Fibrosis
term:
id: NCIT:C178564
label: Cardiac Fibrosis
frequency: VERY_RARE
context: Infantile severe cardiomyopathy
description: >-
Rare cardiac histopathology in which infantile Alstrom cardiomyopathy is
expressed as primary endocardial fibroelastosis with diffuse endocardial
thickening.
evidence:
- reference: PMID:34387706
reference_title: "Recessive ciliopathy mutations in primary endocardial fibroelastosis: a rare neonatal cardiomyopathy in a case of Alstrom syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In this case, the cardiac manifestation in Alstrom syndrome is pEFE."
explanation: Pathology-confirmed case report links infantile Alstrom syndrome to primary endocardial fibroelastosis.
phenotypes:
- category: Ophthalmologic
name: Cone/cone-rod dystrophy
description: >-
Early progressive retinal degeneration involving cones and rods, often
beginning in infancy and driving lifelong visual disability.
frequency: VERY_FREQUENT
diagnostic: true
phenotype_term:
preferred_term: Cone/cone-rod dystrophy
term:
id: HP:0000548
label: Cone/cone-rod dystrophy
evidence:
- reference: PMID:33566311
reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The infantile cone-rod dystrophy with nystagmus and severe visual impairment is the earliest and most consistent clinical manifestation of ALMS."
explanation: Review of ALMS clinical data identifies cone-rod dystrophy as the earliest and most consistent feature.
- category: Ophthalmologic
name: Visual impairment
description: Severe early-onset visual loss caused by progressive retinal degeneration.
frequency: OBLIGATE
phenotype_term:
preferred_term: Visual impairment
term:
id: HP:0000505
label: Visual impairment
evidence:
- reference: PMID:41466426
reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
explanation: Large cohort shows that visual impairment was universal among evaluated patients.
- category: Otologic
name: Sensorineural hearing impairment
description: Progressive, usually symmetric sensory hearing loss beginning in childhood.
frequency: FREQUENT
phenotype_term:
preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: PMID:28573831
reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our data show that hearing loss associated with AS begins in childhood and is a predominantly symmetric, sensory hearing loss that may progress to a severe degree."
explanation: Prospective audiology cohort defines the typical childhood-onset progressive sensory hearing phenotype.
- category: Endocrine/Metabolic
name: Obesity
description: Early-onset obesity, often beginning in childhood and frequently truncal in distribution.
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Obesity
term:
id: HP:0001513
label: Obesity
evidence:
- reference: PMID:41466426
reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
explanation: Large cohort shows obesity in more than 80% of evaluated patients.
- category: Endocrine/Metabolic
name: Insulin resistance
description: Early and often severe insulin resistance complicating obesity in Alstrom syndrome.
phenotype_term:
preferred_term: Insulin resistance
term:
id: HP:0000855
label: Insulin resistance
evidence:
- reference: PMID:32994277
reference_title: "Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Here, we report on a monogenic form of IR-prone obesity, Alström syndrome (ALMS)."
explanation: Human metabolic study explicitly frames ALMS as insulin-resistance-prone obesity.
- category: Endocrine/Metabolic
name: Type II diabetes mellitus
description: Progressive hyperglycemia emerging as insulin resistance worsens over time.
phenotype_term:
preferred_term: Type II diabetes mellitus
term:
id: HP:0005978
label: Type II diabetes mellitus
evidence:
- reference: PMID:33566311
reference_title: "Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In addition, infantile transient cardiomyopathy, early childhood obesity with hyperphagia, deafness, insulin resistance (IR), type 2 diabetes mellitus (T2DM), systemic fibrosis and progressive renal or liver dysfunction are common findings."
explanation: Clinical review supports type II diabetes mellitus as a common downstream metabolic manifestation of ALMS.
- category: Cardiovascular
name: Dilated cardiomyopathy
description: >-
Infantile or later-onset myocardial disease with ventricular dilation and
systolic dysfunction; infantile episodes may partially recover while adult
cardiomyopathy can progress.
frequency: FREQUENT
phenotype_term:
preferred_term: Dilated cardiomyopathy
term:
id: HP:0001644
label: Dilated cardiomyopathy
evidence:
- reference: PMID:17594715
reference_title: "Spectrum of ALMS1 variants and evaluation of genotype-phenotype correlations in Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Alström syndrome is a monogenic recessive disorder featuring an array of clinical manifestations, with systemic fibrosis and multiple organ involvement, including retinal degeneration, hearing loss, childhood obesity, diabetes mellitus, dilated cardiomyopathy (DCM), urological dysfunction, and pulmonary, hepatic, and renal failure."
explanation: Large genotype-phenotype study identifies dilated cardiomyopathy as a core multisystem feature of ALMS.
- reference: PMID:38806112
reference_title: "Defining the cardiovascular phenotype of adults with Alström syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "RESULTS: 47 adults with AS (64% male; mean age 33 years; 66% white British) were studied. Seven (15%) survived infantile cardiomyopathy and 23 (49%) developed adult-onset cardiomyopathy."
explanation: Adult cardiovascular cohort shows cardiomyopathy is frequent across the lifespan.
- category: Renal
name: Chronic kidney disease
description: Age-progressive primary kidney involvement with declining kidney function and proteinuria in a subset of adults.
frequency: OCCASIONAL
phenotype_term:
preferred_term: Chronic kidney disease
term:
id: HP:0012622
label: Chronic kidney disease
evidence:
- reference: PMID:30064963
reference_title: "Alström syndrome: Renal findings in correlation with obesity, insulin resistance, dyslipidemia and cardiomyopathy in 38 patients prospectively evaluated at the NIH clinical center."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Eighteen percent met the definition for chronic kidney disease (eGFR < 60 mL/min/1.73 m2 and proteinuria); all were adults with median age of 32.8 (20.6-37.9) years."
explanation: Prospective NIH cohort quantifies age-progressive chronic kidney disease in adults with ALMS.
- category: Hepatic
name: Hepatic steatosis
description: Common metabolic liver involvement that often coexists with early fibrogenic liver stiffness abnormalities.
frequency: FREQUENT
phenotype_term:
preferred_term: Hepatic steatosis
term:
id: HP:0001397
label: Hepatic steatosis
evidence:
- reference: PMID:41466426
reference_title: "Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Clinical manifestations included universal visual impairment (100%, 112/112), obesity (84.1%, 96/114), hearing loss (70.8%, 51/72), hepatic steatosis (66.7%, 40/60), and cardiac abnormalities (58.2%, 46/79)."
explanation: Large cohort demonstrates frequent hepatic steatosis in ALMS.
treatments:
- name: GLP-1 Receptor Agonist Therapy
description: >-
Semaglutide or exenatide can improve weight, glycemia, and lipid parameters
in adults with Alstrom syndrome and metabolically significant obesity or
diabetes.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
target_phenotypes:
- preferred_term: Obesity
term:
id: HP:0001513
label: Obesity
- preferred_term: Type II diabetes mellitus
term:
id: HP:0005978
label: Type II diabetes mellitus
evidence:
- reference: PMID:38151964
reference_title: "Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "equating to 6% weight loss (P < .01) and 1.1% absolute reduction in HbA1c (P < .01)."
explanation: Real-world ALMS cohort demonstrates clinically meaningful metabolic benefit from GLP-1 receptor agonists.
- name: Hearing aid usage
description: Sound amplification is beneficial for the common progressive sensory hearing loss of Alstrom syndrome.
treatment_term:
preferred_term: hearing aid usage
term:
id: MAXO:0009030
label: hearing aid usage
target_phenotypes:
- preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: PMID:28573831
reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These findings indicate that individuals with AS would benefit from sound amplification and if necessary, cochlear implantation."
explanation: Prospective audiology cohort supports hearing aids as routine symptomatic treatment for ALMS hearing loss.
- name: Cochlear implantation
description: >-
Cochlear implantation should be considered for severe or functionally
limiting hearing loss not adequately managed with amplification.
treatment_term:
preferred_term: surgical procedure
term:
id: MAXO:0000004
label: surgical procedure
target_phenotypes:
- preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
evidence:
- reference: PMID:28573831
reference_title: "Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "These findings indicate that individuals with AS would benefit from sound amplification and if necessary, cochlear implantation."
explanation: Same cohort specifically identifies cochlear implantation as an option for more severe ALMS hearing loss.
notes: >-
Curated as a single ALMS1-related multisystem disease entity rather than split
into separate retinal, cardiomyopathic, or metabolic disorders. Infantile
cardiomyopathy and later adult-onset cardiomyopathy are modeled as
age-dependent manifestations within the same disease.
Alstrom syndrome should be curated as a single ALMS1-related multisystem ciliopathy, not split into separate retinal, cardiomyopathic, renal, or metabolic diseases. The strongest framing papers consistently describe one disorder with age-dependent expression spanning early cone/cone-rod retinal dystrophy, childhood obesity, progressive hearing loss, cardiomyopathy, and later renal/hepatic disease (PMID:11941369, PMID:11941370, PMID:17594715, PMID:41466426).
Infantile cardiomyopathy and adult cardiomyopathy are best treated as distinct manifestations within one disease course, not as separate disorders. Adult cardiovascular phenotyping shows that some infants recover from transient severe cardiomyopathy and later develop adult-onset disease, demonstrating variable expressivity rather than nosologically distinct entities (PMID:38806112).
The most important split decision is against Bardet-Biedl syndrome. Both are syndromic obesity ciliopathies, but Alstrom syndrome is distinguished by early cone/cone-rod dystrophy, progressive sensorineural hearing loss, and cardiomyopathy, while polydactyly and overt neurodevelopmental impairment are not defining Alstrom features. This distinction is reinforced in cohort and review literature used for differential diagnosis (PMID:28573831, PMID:30064963, PMID:39763001).
Alstrom syndrome is an autosomal recessive disorder caused by biallelic ALMS1 pathogenic variants (PMID:11941369, PMID:11941370). The original cloning studies showed recurrent nonsense and frameshift mutations causing premature truncation of ALMS1, establishing loss of function as the canonical disease mechanism (PMID:11941369, PMID:11941370).
Subsequent cohort work showed that pathogenic variants are concentrated especially in exons 8, 10, and 16, although the mutational spectrum is broad and still expanding (PMID:17594715, PMID:41466426). The largest recent Chinese cohort identified 132 distinct ALMS1 variants, 64 of them novel, with truncating variants predominating and exon 16 truncating alleles enriched among infantile cardiomyopathy cases (PMID:41466426).
The core mechanistic lesion is ALMS1 dysfunction at the centrosome and ciliary basal body. Localization studies demonstrated that ALMS1 is widely expressed and localizes to centrosomes and the base of cilia, supporting a basal-body centered mechanism rather than a tissue-restricted defect (PMID:15855349). Kidney and cochlear studies extended this by showing roles in cilium maintenance, mechanosensation, and cilium-dependent planar cell polarity (PMID:17206865, PMID:21071598).
This basal-body lesion branches into several partially separable disease modules:
Sensory-cell degeneration Photoreceptor and cochlear hair-cell maintenance depend on ALMS1. Alms1-disrupted mice show early cone ERG abnormalities followed by photoreceptor loss and rhodopsin mislocalization, supporting a trafficking-dependent retinal degeneration mechanism (PMID:16000322). In the cochlea, ALMS1 localizes to hair-cell basal bodies; loss causes hair-bundle polarity abnormalities, outer hair-cell loss, and progressive sensory hearing loss (PMID:21071598). Human cohort data align with this model: retinal disease is typically earliest, while hearing loss is childhood-onset, symmetric, and progressive (PMID:28573831, PMID:33566311, PMID:41466426).
Adipose tissue failure and insulin-resistant obesity The best current human mechanistic paper is the adipose physiology study showing relative adipose tissue failure in ALMS as a major determinant of accelerated insulin resistance without frank lipodystrophy (PMID:32994277). This provides a stronger disease-specific explanation for the metabolic phenotype than generic statements about obesity alone. Review synthesis further argues that severe insulin resistance and later beta-cell failure together drive type II diabetes mellitus in ALMS (PMID:33566311).
Extracellular matrix dysregulation and fibrosis Fibrosis is not just a descriptive phenotype but a central mechanistic axis of disease. The older genotype-phenotype paper already emphasizes systemic fibrosis (PMID:17594715). More recently, ALMS1 knockout fibroblast profiling showed extracellular matrix regulation and collagen fibril organization among the key processes altered by ALMS1 loss (PMID:38062477). Human liver studies using elastography and ultrasound found enhanced steatosis plus age-related liver stiffness in ALMS, supporting a fibrogenic liver phenotype linked both to metabolic burden and ALMS1-related mechanisms (PMID:33924909).
Primary kidney ciliopathy Renal disease is best modeled as a primary manifestation of ALMS1 deficiency, not just downstream diabetic kidney disease. Mouse work demonstrated stunted kidney epithelial cilia and impaired calcium responses to mechanical stimuli after Alms1 knockdown (PMID:17206865). The NIH human cohort then showed that kidney dysfunction was not explained by diabetes, dyslipidemia, hypertension, cardiomyopathy, or portal hypertension after age adjustment, supporting primary kidney involvement (PMID:30064963).
Cardiac fibroelastotic remodeling Cardiomyopathy in ALMS is mechanistically heterogeneous across the lifespan. Adults frequently develop cardiomyopathy with restrictive features and broader cardiovascular remodeling (PMID:38806112). A pathology-confirmed neonatal case linked ALMS1 deficiency to primary endocardial fibroelastosis, with accompanying EMT/TGF-beta pathway activation and increased cardiomyocyte proliferation in ALMS1-depleted systems (PMID:34387706). This supports keeping infantile fibroelastotic disease and later adult cardiomyopathy within one mechanistic cardiac spectrum rather than treating them as separate diseases.
Only a small number of treatments have disease-specific abstract-level support strong enough for clean curation:
GLP-1 receptor agonists Real-world cohort data in adults with ALMS show reductions in body weight and HbA1c after semaglutide or exenatide, with additional lipid and liver-enzyme improvement (PMID:38151964). This is the strongest current disease-specific obesity/diabetes treatment evidence.
Auditory rehabilitation Prospective single-center audiology data specifically conclude that affected individuals benefit from sound amplification and, when needed, cochlear implantation (PMID:28573831).
General “multidisciplinary management” and “lifestyle modification” recommendations are common in reviews (PMID:33566311), but these are less specific than the GLP-1 and hearing-rehabilitation evidence above.
evidence_source aligned to the study type: